|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Variable in analysis  | Categories of the variable | BZD Users | Non-BZD Users | *Odds ratio*; (IC 95%) | p-value |
| Age | Mean ± SDMin-Max | 46.7 ± 6.831-61 | 46.8 ± 7.127-64 | 0.083; (-1.977, 2.144) | 0.937 |
| Gender | Male | 54 (90.0%) | 161 (91.5%) | 1.193; (0.441, 3.228) | 0.729 |
| Female | 6 (10.0%) | 15 (8.5%) |
| Civil Status | Not Married  | 46 (76.7%) | 113 (64.2%) | 0.546; (0.279, 1.070) | 0.075 |
| Married | 14 (23.3%) | 63 (35.8%) |
| Educational Level | ≤ 9 years | 39 (65.0%) | 121 (69.9%) | 1.253; (0.673, 2.234) | 0.477 |
| > 9 years | 21 (35.0%) | 52 (30.1%) |
| Parental Status | No | 21 (35.0%) | 79 (44.9%) | 1.513; (0.823, 2.778) | 0.181 |
| Yes  | 39 (65.0%) | 97 (55.1%) |
| Professional Status | Not Employed  | 25 (41.7%) | 55 (31.3%) | 0.639; (0.348, 1.164) | 0.141 |
| Employed/Retired  | 35 (58.3%) | 121 (68.8%) |
| Legal Issues | No  | 20 (33.3%) | 59 (33.5%) | 1.009; (0.542, 1.877) | 0.979 |
| Yes | 40 (66.7%) | 117 (66.5%) |
| Convicted to Prison Sentence | No  | 42 (70.0%) | 127 (72.2%) | 1.111; (0.584, 2.113) | 0.749 |
| Yes | 18 (30.0%) | 49 (27.8%) |

 Table 1. Bivariate statistical analysis for sociodemographic characterization

Table 2. Bivariate statistical analysis for BZD Pattern Use and physical outcomes

Note: SD: standard deviation; BZD: benzodiazepine.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Variable in analysis  | Categories of the variable | BZD Users | Non-BZD Users | *Odds ratio or Difference of Means*; (IC 95%) | p-value |
| Daily dose of BUP (mg) | Mean ± SDMin-Max | 6.61 ± 3.202.0-16.0 | 6.13 ± 3.671.5-16.0 | 0.483; (- 1.483, 2.250) | 0.625 |
| Daily dose of MET (mg) | < 60 | 14 (23.3%) | 61 (34.7%) | 1.743; (0.888, 3.420) | 0.111 |
| > 60 | 46 (76.7%) | 115 (65.3%) |
| History of BZD intake in the past | No | 6 (10.0%) | 62 (35.2%) | 4.895; (1.993, 12.019) | < 0.001 |
| Yes  | 54 (90.0%) | 114 (64.8%) |
| HIV | No | 48 (80.0%) | 148 (85.5%) | 1.480; (0.691, 3.169) | 0.311 |
| Yes  | 12 (20.0%) | 25 (14.5%) |
| Hepatitis B | No | 52 (86.7%) | 164 (93.2%) | 2.103; (0.815, 5.423) | 0.118 |
| Yes  | 8 (13.3%) | 12 (6.8%) |
| Hepatitis C | No | 18 (30.0%) | 93 (53.8%) | 2.713; (1.448, 5.082) | 0.001 |
| Yes  | 42 (70.0%) | 80 (46.2%) |
| History of Overdose | No | 48 (80.0%) | 144 (81.8%) | 1.125; (0.537, 2.357) | 0.755 |
| Yes  | 12 (20.0%) | 32 (18.2%) |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Variable in analysis (in the last 30 days) | Categories of the variable | BZD Users | Non-BZD Users | *Odds ratio or Difference of Means*; (IC 95%) | p-value |
| Alcohol consumption | No | 32 (53.3%) | 65 (36.9%) | 0.512; (0.283, 0.927) | 0.026 |
| Yes  | 28 (46.7%) | 111 (63.1%) |
| Cocaine consumption  | No | 50 (83.3%) | 145 (82.4%) | 0.935; (0.428, 2.045) | 0.867 |
| Yes  | 10 (16.7%) | 31 (17.6%) |
| Heroine consumption | No | 55 (91.7%) | 162 (92.0%) | 1.052; (0.362, 3.054) | 1.000 |
| Yes  | 5 (8.3%) | 14 (8.0%) |
| Cannabinoids consumption | No | 35 (58.3%) | 127 (72.2%) | 1.851; (1.006, 3.407) | 0.046 |
| Yes  | 25 (41.7%) | 49 (27.8%) |
| Amphetamines consumption  | No | 60 (100.0%) | 176 (100.0%) | - | - |
| Yes  | 0 (0.0%) | 0 (0.0%) |
| Depression symptoms  | No | 11 (18.3%) | 78 (44.3%) | 3.545; (1.729, 7.272) | < 0.001 |
| Yes  | 49 (81.7%) | 98 (55.7%) |
| Suicide thoughts  | No | 49 (81.7%) | 168 (95.5%) | 4.714; (1.797, 12.370) | 0.002 |
| Yes  | 11 (18.3%) | 8 (4.5%) |
| Anxiety  | No | 7 (11.7%) | 79 (44.9%) | 6.166; (2.656, 14.317) | < 0.001 |
| Yes  | 53 (88.3%) | 97 (55.1%) |
| Irritability and anger  | No | 40 (66.7%) | 127 (72.2%) | 1.296; (0.690, 2.433) | 0.419 |
| Yes  | 20 (33.3%) | 49 (27.8%) |

 Table 3. Bivariate statistical analysis for psychiatric outcomes

Note: BZD: benzodiazepine.

Table 4. Optimized Logistic Regression Model

|  |  |  |  |
| --- | --- | --- | --- |
| Variable in analysis | Categories of the variable | *Odds ratio*; (IC 95%) | p-value |
| History of BZD intake in the past  | No | 3.726; (1.444, 9.617) | 0.007 |
| Yes  |
| Yes  |
| Alcohol consumption in the last 30 days | No | 0.482; (0.247, 0.238) | 0.032 |
| Yes  |
| Anxiety  | No | 5.591; (2.345, 13.326) | < 0.001 |
| Yes  |
| Hepatitis C | No | 2.544; (1.273, 5.084) | 0.008 |
| Yes  |

 Note: BZD: benzodiazepine.